/pharmaceuticals/oncology/Sanofi-buy-natural-killer-cell/98/i43 20201108 Concentrates 98 43 /magazine/98/09843.html Sanofi to buy natural killer cell company Kiadis oncology, pharmaceuticals, natural killer cells, sanofi, kiadis con bus Ryan Cross pharmaceuticals oncology business mergers-&-acquisitions Sanofi to buy natural killer cell firm Kiadis Chemical & Engineering News Sanofi to buy natural killer cell company Kiadis Sanofi to buy natural killer cell company Kiadis
by Ryan Cross | November 08, 2020
/pharmaceuticals/oncology/Merck-buy-antibody-drug-conjugate/98/i43 20201108 Concentrates 98 43 /magazine/98/09843.html Merck to buy antibody-drug conjugate developer VelosBio Antibody-drug conjugates, oncology, Merck con bus Ryan Cross pharmaceuticals oncology Merck to buy ADC developer VelosBio Chemical & Engineering News Merck to buy antibody-drug conjugate developer VelosBio Merck to buy antibody-drug conjugate developer VelosBio
by Ryan Cross | November 08, 2020
The goal is to bind the α-emitting isotope actinium-225 to antibodies in AstraZeneca’s oncology drug portfolio. Merck KGaA will be the contract manufacturer for Mammoth Biosciences’ new CRISPR-based SARS-CoV-2 diagnostic kit, for which it recently won funding from the US National Institutes of Health.
November 08, 2020
/analytical-chemistry/diagnostics/Exact-Sciences-acquires-liquid-biopsy/98/i42 20201031 Concentrates 98 42 /magazine/98/09842.html Exact Sciences acquires liquid-biopsy start-up Thrive in $2.15 billion deal diagnostics, pharmaceuticals, oncolgoy, liquid biopsy, exact sciences, thrive con bus Ryan Cross analytical-chemistry diagnostics pharmaceuticals oncology business mergers-&-acquisitions Exact Sciences buys liquid-biopsy start-up Chemical & Engineering News Exact Sciences acquires liquid-biopsy start-up Thrive in $2.15 billion deal Exact Sciences acquires liquid-biopsy start-up Thrive in $2.15 billion deal
by Ryan Cross | October 31, 2020
/biological-chemistry/cancer/Targeting-tumor-specific-T-cells/98/i41 20201024 Cell-enzyme conjugate can quickly and specifically label T cells that could be used for cancer therapies Concentrates 98 41 /magazine/98/09841.html Targeting tumor-specific T cells Cancer, T-cells, sugar chemistry con scitech Laura Howes biological-chemistry cancer pharmaceuticals oncology biological-chemistry synthetic-biology The bait cell–enzyme conjugate quickly and specifically adds a biotin label (B) to the sugars (colored shapes) on the surface of tumor-specific T cells.
by Laura Howes | October 24, 2020
But as Mischel’s glioblastoma research showed, this precision oncology approach doesn’t always work, particularly when trying to block proteins made by genes on DNA circles. Figuring out what to do about ecDNA may be even harder than studying it. Since we still don’t know how the creation or reintegration of ecDNA is controlled, Henssen thinks the best strategy for drug developers might be targeting ecDNA-dependent cells indirectly.
by Ryan Cross | October 18, 2020
/pharmaceuticals/oncology/RayzeBio-garners-45-million-series/98/i40 20201017 Concentrates 98 40 /magazine/98/09840.html RayzeBio garners $45 million in series A funding for radiopharmaceuticals Biotech, pharmaceuticals, radiochemistry con bus Megha Satyanarayana pharmaceuticals oncology Radiopharmaceutical firm gets first funding Chemical & Engineering News RayzeBio garners $45 million in series A funding for radiopharmaceuticals RayzeBio garners $45 million in series A funding for radiopharmaceuticals
by Megha Satyanarayana | October 17, 2020
/pharmaceuticals/oncology/Priothera-raises-35-million-leukemia/98/i40 20201017 Concentrates 98 40 /magazine/98/09840.html Priothera raises $35 million for leukemia therapy oncology, pharmaceuticals, mocravimod, priothera, leukemia con bus Ryan Cross pharmaceuticals oncology business start-ups This is a structure of mocravimod. structure Mocravimod Priothera raises funds for leukemia therapy Chemical & Engineering News Priothera raises $35 million for leukemia therapy Priothera raises $35 million for leukemia therapy
by Ryan Cross | October 17, 2020
And that’s not just for oncology or immuno-oncology. You can imagine you can go into any area of biology where you want to understand the microenvironment of a particular protein. What excites you about the work that you’re doing? Thirty or 40 years ago, the way we did medicinal chemistry and the way we did science were completely different.
by Tien Nguyen, special to C&EN | October 17, 2020
/business/start-ups/Pfizer-invests-China-based-CStone/98/i38 20201002 Concentrates 98 38 /magazine/98/09838.html Pfizer invests in China-based CStone Biotechnology, Pfizer, oncology con bus Lisa M. Jarvis business start-ups pharmaceuticals oncology Pfizer invests in China-based CStone Chemical & Engineering News Pfizer invests in China-based CStone Pfizer invests in China-based CStone
by Lisa M. Jarvis | October 02, 2020